Skip to content
Future of British Business

GSK Aims to Deliver First RSV Vaccine After Positive Results

  • Drugmaker plans to file with regulators in second half of year
  • Data give GSK a boost after stumbling in Covid vaccine race
Updated on

GSK Plc said its vaccine targeting a respiratory virus that causes hundreds of thousands of hospitalizations in older adults each year delivered positive results in a trial, a boost for the drugmaker after falling behind in the quest to develop a Covid shot.

The vaccine against respiratory syncytial virus, or RSV, surpassed its primary goal in the study without safety concerns, becoming the first to show significant efficacy in adults over 60, the company said in a statement Friday. The UK pharmaceutical giant said it expects to file with regulators in the second half of the year. GSK shares rose as much as 2.7% in London.